The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to Med Watch, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: mmancano@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's Med Watch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.
展开▼
机译:此功能的目的是提高对特定药物不良反应 (ADR) 的认识,讨论预防方法,并促进向美国食品和药物管理局 (FDA) 的 MedWatch 计划 (800-FDA-1088) 报告 ADR。如果您向 Med Watch 报告了有趣的、可预防的 ADR,请考虑与我们的读者分享该帐户。写信给 ISMP 的 Mancano 博士,地址为 200 Lakeside Drive, Suite 200, Horsham, PA 19044(电话:215-707-4936;电子邮件:mmancano@temple.edu)。除非另有要求,否则您的报告将匿名发布。此功能由安全用药实践研究所 (ISMP) 与 FDA 的 Med Watch 计划和天普大学药学院合作提供。ISMP 是 FDA MedWatch 的合作伙伴。
展开▼